PT-141 Research: Overview, Mechanism & Data for Labs

PT-141, also known as Bremelanotide, is a synthetic melanocortin-receptor agonist that has been a focal point in neuroendocrine and sexual-health research. Its unique mechanism of action involves modulation of central melanocortin pathways, prompting considerable scientific inquiry into its potential physiological effects. The extensive body of work surrounding PT-141 is evidenced by 108 indexed publications on PubMed and 4 registered studies on ClinicalTrials.gov, highlighting its significance as a research compound.

This reference page provides a comprehensive overview of PT-141’s chemical properties, proposed mechanism of action, and the landscape of investigations exploring its interactions within various biological systems, strictly for laboratory and academic research purposes.

Introduction to PT-141 (Bremelanotide) in Research

PT-141, also known by its research alias Bremelanotide, stands as a prominent investigational compound within the field of neuroendocrinology and sexual-health research. Classified as a melanocortin agonist, this synthetic peptide serves as a valuable tool for exploring the intricate mechanisms of the central melanocortin system. Its utility in research is primarily centered on elucidating pathways involved in various physiological processes, particularly those governing neuroendocrine regulation and central pathways related to sexual function. The robust scientific interest in PT-141 is underscored by its extensive documentation in peer-reviewed literature and registered clinical investigations.

The research landscape surrounding PT-141 is broad and continually expanding, reflecting its potential to shed light on complex biological systems. To date, a significant body of evidence has been compiled, with approximately 108 publications indexed in PubMed detailing a wide array of preclinical studies, mechanistic investigations, and translational research efforts. Furthermore, its progression into human-focused inquiries is highlighted by 4 registered studies on ClinicalTrials.gov, which aim to further characterize its effects and safety profiles under strictly controlled research protocols. These studies contribute to a growing understanding of how modulation of the melanocortin system can influence central nervous system-mediated responses.

As a research compound, PT-141 offers researchers a specific pharmacological probe to investigate the roles of melanocortin receptors independently of endogenous ligand fluctuations. This precision allows for controlled experimentation aimed at dissecting signaling cascades and their downstream physiological consequences. Understanding its fundamental properties and mechanism of action is paramount for designing robust and interpretable research studies, from isolated cell systems to complex in vivo models. For researchers new to peptide compounds, understanding what constitutes a research peptide can provide a useful foundation.

Chemical Characterization and Physicochemical Properties of PT-141

PT-141, or Bremelanotide, is a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH. This specific sequence dictates its distinct pharmacological profile and physicochemical attributes. The presence of a D-phenylalanine residue (D-Phe) at position 7 and an N-terminal acetyl group, along with the cyclic structure formed by the aspartic acid and lysine residues, are critical modifications that enhance its metabolic stability and receptor binding specificity compared to naturally occurring melanocortin peptides like alpha-melanocyte-stimulating hormone (α-MSH).

Molecular Structure and Stability

The molecular weight of PT-141 is approximately 976.14 g/mol, a characteristic that influences its pharmacokinetic properties in research models. Its cyclic structure imparts increased resistance to enzymatic degradation by peptidases, thereby prolonging its half-life in biological systems and making it a more stable research tool for sustained receptor agonism. This enhanced stability is a significant advantage for both in vitro and in vivo investigations, ensuring consistent compound exposure over experimental durations. Researchers must maintain strict handling and storage protocols to preserve its integrity, as detailed in resources concerning PT-141 storage and handling.

Solubility and Purity Considerations

For research applications, PT-141 typically demonstrates good solubility in aqueous solutions, particularly those containing a small percentage of organic co-solvents (e.g., acetonitrile) or at slightly acidic pH, which facilitates its preparation for various experimental setups. Achieving high purity is paramount for reproducible and reliable research outcomes. Impurities, even in trace amounts, can confound results by introducing unintended pharmacological activities or altering the peptide’s inherent properties. Therefore, researchers rely on meticulously characterized compounds, often accompanied by a Certificate of Analysis (CoA), ensuring the peptide meets stringent purity standards for research use. Analytical techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) are routinely employed to confirm the identity and purity of PT-141 batches used in rigorous scientific inquiry.

Overview of the Central Melanocortin System and Receptors

The central melanocortin system constitutes a crucial neuroendocrine pathway involved in regulating a diverse array of physiological functions, including energy homeostasis, inflammation, pain modulation, and sexual function. At its core, this system comprises the pro-opiomelanocortin (POMC) neuronal circuits, which produce endogenous melanocortin peptides, and a family of G-protein coupled receptors (GPCRs) known as melanocortin receptors (MCRs). Understanding this foundational system is key to appreciating the mechanistic role of PT-141 as a selective melanocortin agonist.

Melanocortin Receptor Family

There are five distinct melanocortin receptors (MC1R-MC5R) identified in mammals, each encoded by a separate gene and exhibiting unique tissue distribution and physiological roles. These receptors are primarily Gs-protein coupled, meaning their activation typically leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, which subsequently modulates downstream signaling pathways. The primary endogenous ligands for these receptors are derived from the proteolytic cleavage of the POMC precursor peptide, including alpha-melanocyte-stimulating hormone (α-MSH), beta-MSH, gamma-MSH, and adrenocorticotropic hormone (ACTH).

The functional diversity of the melanocortin system is largely attributable to the differential expression and ligand binding specificities of these receptors. For instance, MC1R is predominantly found in melanocytes and plays a role in skin pigmentation, while MC2R is exclusively expressed in the adrenal cortex and is the receptor for ACTH. Of particular relevance to PT-141 research are MC3R and MC4R, which are widely expressed within the central nervous system and are critically involved in neuroendocrine regulation and the control of central pathways related to sexual function. The following table provides a brief overview of the known melanocortin receptors:

Receptor Type	Primary Tissue Distribution (Research Context)	Key Endogenous Ligands	Associated Research Areas (Central/Neuroendocrine)
MC1R	Melanocytes, immune cells	α-MSH	Pigmentation, anti-inflammatory effects
MC2R	Adrenal cortex	ACTH	Adrenal steroidogenesis
MC3R	Hypothalamus, limbic system, brainstem	γ-MSH, α-MSH	Energy homeostasis, sexual function, inflammation
MC4R	Hypothalamus, hippocampus, brainstem, spinal cord	α-MSH	Energy homeostasis, sexual function, blood pressure, pain modulation
MC5R	Exocrine glands, immune cells, CNS	α-MSH	Sebum production, immune function, CNS effects

PT-141’s mechanism as a melanocortin agonist is therefore intrinsically linked to its ability to interact with these receptors, particularly MC3R and MC4R, within the central nervous system. By selectively modulating the activity of these receptors, researchers can investigate their roles in various physiological and behavioral responses. Further details on this specific interaction are elaborated in the section on PT-141’s Specific Mechanism of Action: MCR Binding Profile.

PT-141’s Specific Mechanism of Action: MCR Binding Profile

PT-141, also known as bremelanotide, functions as a synthetic melanocortin receptor agonist, a class of peptides extensively studied for their influence on neuroendocrine regulation and central nervous system (CNS)-mediated responses, particularly those related to sexual function. Its primary mechanism involves binding to and activating specific G protein-coupled receptors (GPCRs) within the melanocortin system. This system is comprised of five receptor subtypes (MC1R-MC5R), each distributed in distinct tissues and mediating diverse physiological functions. For researchers studying PT-141’s effects, understanding its precise receptor binding profile is crucial for elucidating its observed actions.

Research indicates that PT-141 exhibits a high binding affinity and agonistic activity predominantly at the melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R). While it also shows some affinity for MC1R, its actions are primarily attributed to MC3R and MC4R activation, with MC4R widely considered the principal mediator of its influence on central pathways governing sexual arousal. The MC4R is richly expressed in various brain regions critical for neuroendocrine function and sexual behavior, including the hypothalamus, preoptic area, and limbic system. The specificity of PT-141’s binding to these receptors, particularly MC4R, distinguishes its mechanism from other melanocortin agonists and contributes to its unique pharmacological profile under investigation.

Compared to the endogenous melanocortin peptide alpha-melanocyte-stimulating hormone (α-MSH), PT-141 offers certain advantages for research due to its enhanced stability and a more focused receptor activation profile. Studies have shown that PT-141’s agonistic activity at MC3R and MC4R leads to robust and sustained signaling cascades, which are key to understanding its potential as a research tool. The careful characterization of this binding profile in various PT-141 mechanism of action studies highlights its utility in dissecting the complex roles of melanocortin signaling in the CNS.

Intracellular Signaling Pathways Activated by PT-141 Agonism

The activation of melanocortin receptors by PT-141 initiates a cascade of intracellular signaling events characteristic of G protein-coupled receptors. Upon PT-141 binding to MC3R or MC4R, these receptors undergo a conformational change, leading to the activation of associated G proteins. Melanocortin receptors are primarily coupled to stimulatory G_s proteins. The activation of G_s subunits then stimulates the enzyme adenylyl cyclase (AC), which is membrane-bound.

Adenylyl cyclase, upon activation, catalyzes the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The increase in intracellular cAMP levels is a critical second messenger event following PT-141 agonism. Elevated cAMP subsequently activates protein kinase A (PKA), a serine/threonine kinase. PKA then phosphorylates various downstream target proteins, including transcription factors such as cAMP response element-binding protein (CREB), ion channels, and other enzymes. This phosphorylation alters the activity, localization, or stability of these target proteins, ultimately leading to changes in gene expression, neuronal excitability, and synaptic plasticity.

While the cAMP-PKA pathway is the predominant signaling route, researchers also investigate potential cross-talk with other signaling pathways or modulatory mechanisms. For instance, prolonged GPCR activation can lead to receptor desensitization and internalization, often mediated by G protein-coupled receptor kinases (GRKs) and β-arrestins. Although these are typically considered negative feedback loops, β-arrestin can also serve as a scaffold for alternative signaling pathways, such as extracellular signal-regulated kinase (ERK) cascades. Understanding the nuances of these intracellular events is vital for comprehending the full scope of PT-141’s actions within neuroendocrine cells and neurons.

Key Intracellular Signaling Steps:

PT-141 binds to MC3R/MC4R.
Conformational change in the receptor activates G_s protein.
G_s protein activates adenylyl cyclase.
Adenylyl cyclase converts ATP to cAMP.
Increased cAMP levels activate Protein Kinase A (PKA).
PKA phosphorylates downstream target proteins (e.g., CREB, ion channels).
Changes in protein activity and gene expression mediate physiological responses.

Preclinical In Vitro Models for PT-141 Investigations

Preclinical in vitro models are indispensable tools in the early stages of PT-141 research, allowing investigators to characterize its fundamental pharmacological properties in a controlled environment. These models help determine receptor binding affinity, selectivity, potency, and efficacy at a cellular or molecular level before progressing to more complex in vivo studies. They provide insights into the direct effects of PT-141 on specific cell types expressing melanocortin receptors, isolated from the complexities of systemic physiological interactions.

Common In Vitro Models and Assays:

Researchers frequently employ several types of cell lines and assays for PT-141 investigations:

Receptor Binding Assays: Using membranes from cells heterologously expressing human MC3R or MC4R (e.g., HEK293 cells), competitive radioligand binding assays are performed to determine PT-141’s affinity (K_i) for these receptors. These assays often involve a labeled reference ligand to compete with varying concentrations of PT-141.
Functional Assays: To assess PT-141’s ability to activate downstream signaling, functional assays are critical. These include:
- cAMP Accumulation Assays: Measuring the increase in intracellular cAMP levels in response to PT-141 treatment, typically using luminescence- or fluorescence-based reporter systems. This directly quantifies adenylyl cyclase activation.
- Reporter Gene Assays: Cells transfected with a cAMP-responsive element (CRE)-driven reporter gene (e.g., luciferase) can be used to monitor PKA activation and downstream gene transcription.
- Calcium Mobilization Assays: While not the primary pathway for MC4R, some studies explore potential calcium flux changes, particularly in specific neuronal contexts or with high agonist concentrations.
Cell-Based Electrophysiology: For studying neuronal excitability, patch-clamp recordings on cultured neurons (e.g., hypothalamic neurons) or cells expressing MCRs can assess changes in membrane potential or ion channel activity in response to PT-141.
Gene and Protein Expression Studies: Techniques like RT-qPCR and Western blot analysis can be used to investigate how chronic or acute PT-141 exposure affects the expression levels of MCRs themselves, downstream signaling components, or target genes implicated in neuroendocrine regulation.

The success and reliability of in vitro studies with PT-141 heavily depend on the purity and integrity of the research peptide. Rigorous quality testing, including mass spectrometry and HPLC, is essential to confirm the identity, purity, and concentration of the PT-141 used, ensuring that observed effects are truly attributable to the compound and not to impurities or degradation products. While invaluable for initial characterization, it is important to acknowledge that in vitro models lack the complex physiological environment, neural circuitry, and systemic feedback mechanisms present in living organisms, necessitating subsequent in vivo studies.

In Vivo Animal Studies Exploring PT-141’s Effects on Neuroendocrine Regulation

Research involving PT-141, a melanocortin receptor agonist, has extensively utilized various animal models to elucidate its influence on the intricate neuroendocrine system. The melanocortin system itself is a critical modulator of numerous physiological processes, including stress responses, energy homeostasis, and the hypothalamic-pituitary axes. By engaging specific melanocortin receptors (MCRs) within the central nervous system, PT-141 exhibits a capacity to modulate diverse endocrine pathways, underscoring its potential as a research tool for understanding these complex regulatory networks.

Modulation of Hypothalamic-Pituitary Axes and Stress Response

Investigations in rodent models have explored PT-141’s impact on the hypothalamic-pituitary-adrenal (HPA) axis, a central component of the stress response. Studies have reported that PT-141 can influence the release of adrenocorticotropic hormone (ACTH) and subsequent corticosteroid production (e.g., corticosterone in rodents), suggesting a role in central stress modulation. This agonistic activity at MCRs in specific brain regions, such as the paraventricular nucleus of the hypothalamus, points to a mechanism by which PT-141 may alter physiological and behavioral responses to stressors in animal subjects, providing insight into the neurobiological underpinnings of stress regulation.

Beyond the HPA axis, PT-141’s neuroendocrine influence extends to other pathways. Research has also touched upon its potential, albeit often indirect, to affect the hypothalamic-pituitary-gonadal (HPG) axis, primarily through its well-documented effects on sexual function which in turn can feed back into reproductive hormone regulation. Furthermore, the melanocortin system is intrinsically linked to metabolic regulation. Animal studies have investigated how PT-141 might influence central pathways controlling appetite and energy expenditure, indicating its role in broader neuroendocrine feedback loops that govern energy balance, independent of specific weight-loss outcomes.

Summary of PT-141’s Neuroendocrine Research Areas in Animal Models

Neuroendocrine Axis/System	Observed Effects (in Animal Models)	Key Research Focus
Hypothalamic-Pituitary-Adrenal (HPA)	Modulation of ACTH and corticosteroid release	Stress response, anxiety-like behaviors
Hypothalamic-Pituitary-Gonadal (HPG)	Indirect effects on gonadotropin-releasing hormone (GnRH) and gonadotropin release	Reproductive regulation, interplay with sexual function
Metabolic Regulation	Influence on central pathways for food intake, energy expenditure, glucose homeostasis	Obesity models, diabetes research (central mechanisms)

Research into PT-141’s Impact on Central Pathways Related to Sexual Function

One of the most extensively studied applications of PT-141 in animal research is its profound impact on central pathways governing sexual function. Unlike compounds that primarily affect peripheral vascular mechanisms, PT-141 exerts its effects directly within the brain, acting as a potent melanocortin receptor agonist. This central mechanism of action allows researchers to investigate the intricate neurobiological processes that mediate sexual arousal, desire, and response in various animal models, providing valuable insights into the fundamental mechanisms of sexual behavior.

Pro-Sexual Effects in Rodent Models

Numerous preclinical studies have demonstrated PT-141’s pro-sexual effects in both male and female rodent models. In male rats, administration of PT-141 has been observed to induce penile erections, often characterized by an increase in non-contact erections and decreases in ejaculatory latency, indicating an enhancement of specific aspects of sexual response. In female rats, research has shown that PT-141 can facilitate lordosis, a posture indicative of sexual receptivity, and increase sexual motivation parameters. These findings across sexes highlight the broad central influence of PT-141 on diverse aspects of sexual behavior in rodents, from physiological responses to motivational drives.

Neurochemical Pathways and Non-Human Primate Studies

The central mechanism underlying PT-141’s pro-sexual effects primarily involves the activation of melanocortin-4 receptors (MCR-4) within key brain regions. Specific areas such as the paraventricular nucleus (PVN) of the hypothalamus and the medial preoptic area are critical for the integration of sexual stimuli and the generation of appropriate behavioral and physiological responses. Agonism at MCR-4 in these regions is thought to lead to the downstream release of pro-sexual neurotransmitters, including dopamine in the mesolimbic pathway, associated with reward and motivation, and oxytocin, known for its role in social bonding and sexual arousal. Further exploration into these specific receptor interactions and their downstream signaling cascades can be found in discussions of the PT-141 mechanism of action.

Beyond rodents, research has also extended to non-human primate models, where PT-141 has been observed to elicit similar pro-sexual responses, reinforcing the conserved nature of the melanocortin system’s role in regulating sexual function across mammalian species. These studies are crucial for bridging findings from simpler models to more complex neurobiological systems, further validating the central melanocortin pathway as a significant mediator of sexual behavior.

Exploration of PT-141’s Influence on Other CNS-Mediated Responses

While the effects of PT-141 on neuroendocrine regulation and sexual function have received significant attention in research, the widespread distribution of melanocortin receptors throughout the central nervous system suggests that PT-141, as an MCR agonist, may exert influence over a broader spectrum of CNS-mediated responses. Investigations have begun to explore these additional facets in animal models, seeking to uncover the full extent of the melanocortin system’s involvement in complex brain functions beyond its primary research applications.

Pain Perception and Analgesia

Research has indicated a potential role for the melanocortin system in modulating pain perception, and consequently, PT-141 has been investigated for its possible antinociceptive properties in animal models. Studies employing various pain paradigms, such as thermal, mechanical, and inflammatory pain models, have shown that MCR agonists can exert analgesic effects, suggesting that PT-141 may centrally modulate pain pathways. This involves interactions with descending pain inhibitory pathways originating in the brainstem, potentially offering a novel avenue for understanding central mechanisms of pain control, distinct from traditional opioid pathways.

Cognitive and Behavioral Effects

The melanocortin system’s presence in brain regions associated with cognition and behavior has led researchers to explore PT-141’s potential influence on these domains. Animal studies have probed its effects on learning and memory tasks, anxiety-like behaviors, and depression-like states. While findings can be complex and context-dependent, some research has indicated that melanocortin receptor activation might play a role in modulating stress-induced cognitive impairments or altering emotional responses in rodent models. These investigations contribute to a deeper understanding of how central melanocortin signaling can impact neurocognitive functions and affective states, offering avenues for further basic research.

Thermoregulation and Inflammation

The central melanocortin system is also known to participate in the regulation of body temperature and inflammatory responses. Animal research has explored whether PT-141, through its MCR agonism, can influence thermoregulatory processes, potentially leading to alterations in core body temperature. Furthermore, given the role of melanocortin peptides in central anti-inflammatory effects, studies have investigated if PT-141 can modulate neuroinflammatory responses in the brain. These explorations contribute to a holistic understanding of the melanocortin system’s physiological roles and PT-141’s multifaceted impact on CNS-mediated homeostasis in research models.

Considerations for Peptide Synthesis, Purity, and Storage in PT-141 Research

The integrity and reproducibility of research involving PT-141, also known as Bremelanotide, are critically dependent on the quality of the peptide compound utilized. As a synthetic melanocortin agonist, PT-141 is typically synthesized through established peptide synthesis methodologies. The most common approach for producing such peptides on a research scale is Solid-Phase Peptide Synthesis (SPPS). This technique allows for the sequential addition of protected amino acid residues to a growing peptide chain anchored to an insoluble resin, followed by cleavage and deprotection. Careful control over reaction conditions, reagent quality, and purification steps during SPPS is paramount to minimizing the formation of impurities such as deletion sequences, incomplete sequences, and racemized products, which can significantly confound experimental results by altering receptor binding profiles or introducing off-target effects.

Assessing and Ensuring Purity for Research

For any rigorous scientific investigation, the purity of PT-141 must be analytically verified. High-Performance Liquid Chromatography (HPLC) is the gold standard for assessing peptide purity and quantifying the percentage of the target compound relative to impurities. Researchers typically aim for purity levels exceeding 95%, with many demanding ≥98% for critical experiments. Beyond purity, the structural identity of PT-141 must be confirmed using techniques like Mass Spectrometry (MS) to verify its precise molecular weight and amino acid sequence, and Nuclear Magnetic Resonance (NMR) spectroscopy for detailed structural elucidation. The presence of even minor impurities can introduce variability in research outcomes, particularly when investigating dose-response relationships or specific receptor interactions. Rigorous quality control, including the provision of a Certificate of Analysis (CoA) detailing purity and identity, is thus an indispensable requirement for research-grade PT-141.

Optimal Storage and Handling Protocols

Proper storage and handling are essential to maintain the stability and biological activity of PT-141 throughout its research lifecycle. As a peptide, PT-141 is susceptible to degradation via various mechanisms, including hydrolysis, oxidation, and aggregation, especially when exposed to elevated temperatures, light, or moisture. To mitigate these risks, PT-141 is typically supplied as a lyophilized (freeze-dried) powder. In this solid state, it should be stored in a cool, dark, and dry environment, ideally at -20°C or colder, to preserve its stability for extended periods. Once reconstituted, typically with bacteriostatic water or a sterile saline solution, the peptide’s stability is significantly reduced. Reconstituted PT-141 should be divided into single-use aliquots to avoid repeated freeze-thaw cycles, which can lead to degradation and loss of activity, and stored refrigerated (2-8°C) for short-term use, or refrozen at -20°C for longer periods. Careful adherence to these storage guidelines, detailed further in resources such as PT-141 Storage and Handling, is critical for ensuring consistent experimental results and maximizing the utility of the research compound.

Analytical Techniques for Characterizing PT-141 and its Metabolites in Research Settings

Effective research into PT-141 requires robust analytical methods to characterize the parent compound and identify its metabolic fate within various experimental systems. Understanding the chemical properties, stability, and breakdown products of PT-141 is fundamental for interpreting preclinical pharmacological and toxicological data. Chromatographic and spectrometric techniques form the backbone of these analytical investigations, providing the means to separate, identify, and quantify PT-141 and its related substances in complex matrices.

Chromatographic and Spectrometric Characterization

High-Performance Liquid Chromatography (HPLC) coupled with various detectors is indispensable for assessing the purity and quantifying PT-141. UV-Vis detection is commonly employed due to the peptide bond’s absorbance, while more sensitive and specific detection can be achieved with fluorescence detectors if the peptide or its derivatives possess inherent fluorescence. For definitive identification and structural confirmation, HPLC is frequently coupled with Mass Spectrometry (LC-MS/MS). This powerful hyphenated technique allows researchers to determine the exact molecular weight of PT-141, identify any impurities, and confirm its primary structure through fragmentation patterns. Furthermore, Nuclear Magnetic Resonance (NMR) spectroscopy offers detailed insights into the three-dimensional structure and conformation of PT-141, which can be critical for understanding its receptor binding characteristics and potential structure-activity relationships. Circular Dichroism (CD) spectroscopy can also be used to study the secondary structure of the peptide and its changes under different conditions, such as solvent environment or temperature.

The application of these techniques extends beyond initial characterization. During stability studies, researchers use HPLC and LC-MS/MS to monitor PT-141 degradation over time under various stress conditions (e.g., pH, temperature, light exposure) to establish shelf-life and optimal storage parameters. In pharmacokinetic (PK) and pharmacodynamic (PD) research, these methods are adapted for bioanalytical quantification, where PT-141 levels are measured in biological samples like plasma, urine, or tissue homogenates from animal models. This requires highly sensitive and selective assays, often involving solid-phase extraction or liquid-liquid extraction prior to LC-MS/MS analysis, to separate the peptide from endogenous matrix components and detect it at low physiological concentrations.

Metabolite Identification and Quantification

Investigating the metabolic pathways of PT-141 is crucial for understanding its physiological disposition and potential for active or inactive metabolites. Metabolite identification typically employs LC-MS/MS in conjunction with various fragmentation strategies. By analyzing the mass-to-charge ratio shifts and fragmentation patterns of potential metabolites compared to the parent compound, researchers can deduce modifications such as proteolytic cleavage, oxidation, or conjugation. For instance, specific enzymes in liver microsomes or plasma can be studied in vitro to determine their role in PT-141 degradation. Quantitative analysis of these metabolites in vivo, using methods like LC-MS/MS, allows researchers to assess the extent of metabolism, identify major metabolic pathways, and correlate metabolite exposure with observed biological effects in preclinical models. This comprehensive analytical approach provides a foundation for interpreting the complex pharmacology of PT-141 and guiding further research into its mechanism of action and effects on neuroendocrine regulation and sexual function.

Review of the PT-141 Research Landscape: Key Themes from 108 PubMed Publications

The extensive body of research surrounding PT-141 (Bremelanotide) is reflected in over 100 indexed publications on PubMed, totaling 108 studies at the time of this review. These investigations collectively paint a detailed picture of PT-141 as a melanocortin-receptor agonist with a particular focus on its interactions within neuroendocrine systems and its role in modulating central pathways related to sexual function. The breadth of these publications encompasses a range of experimental designs, from in vitro receptor binding and signaling assays to complex in vivo animal models exploring physiological and behavioral responses.

Neuroendocrine Research Trajectories

A significant portion of the PubMed literature delves into PT-141’s interaction with the central melanocortin system. Research has consistently demonstrated PT-141’s agonistic activity at melanocortin receptors, specifically MCR3 and MCR4, located predominantly in the central nervous system. These receptors are known to play critical roles in diverse neuroendocrine functions, including energy homeostasis, pain processing, and inflammation. Studies have explored how PT-141’s activation of these receptors influences hypothalamic circuits, impacting downstream endocrine signaling. For instance, investigations have touched upon the peptide’s modulation of neuronal activity in key brain regions associated with stress responses and homeostatic regulation. While the primary focus remains on sexual health applications, the broader neuroendocrine impact, including potential influence on inflammatory pathways or appetite regulation, has been an area of exploratory research within the preclinical context, often as a means to fully characterize the compound’s MCR pharmacology.

Investigations into Sexual Function Pathways

The most prominent theme within the 108 PubMed publications centers on PT-141’s unique mechanism of action in modulating central pathways related to sexual function. Research has elucidated that PT-141 exerts its effects by activating MCR4 receptors in specific brain regions, notably the paraventricular nucleus (PVN) of the hypothalamus, which is a crucial hub for integrating neural and endocrine signals involved in sexual arousal and desire. Unlike peripherally acting agents that target vascular smooth muscle, PT-141’s central mechanism involves a cascade of neuronal events that culminate in a pro-sexual response. Preclinical studies using various animal models have consistently demonstrated that PT-141 can induce pro-erectile effects and increase sexual receptivity, supporting the hypothesis of its central site of action. The extensive research in this area has utilized diverse methodologies, including intracranial injections, electrophysiological recordings, and behavioral assays, to map the neural circuitry involved in PT-141’s effects on sexual behavior.

Emerging and Peripheral Research Avenues

While the core of PT-141 research has focused on its central melanocortin agonism and impact on sexual function, the PubMed literature also reveals some exploratory investigations into other potential areas. Given the widespread distribution of melanocortin receptors throughout the body, some studies have explored PT-141’s peripheral effects or its interaction with other neuroendocrine axes beyond sexual function. These investigations, though fewer in number compared to those focused on sexual health, contribute to a comprehensive understanding of PT-141’s pharmacology and its potential broader physiological implications in a research context. This diverse research landscape underscores the multifaceted nature of the melanocortin system and the ongoing scientific interest in understanding the full scope of PT-141’s actions, as further detailed in the overarching PT-141 Research overview.

Analysis of Registered Studies on ClinicalTrials.gov Related to PT-141

ClinicalTrials.gov serves as a comprehensive registry for a wide range of human research studies, providing valuable insights into the ongoing investigation of various compounds and interventions. For PT-141, also known as Bremelanotide, four distinct studies are registered on this platform. These registrations signify a focused research interest in understanding the compound’s effects within controlled human research settings, particularly given its established role as a melanocortin receptor agonist and its relevance in neuroendocrine and sexual-health research contexts.

The registered studies generally explore PT-141’s pharmacodynamics and pharmacokinetics, aiming to elucidate its physiological impact on various systems. Researchers typically design these investigations to gather data on compound administration, participant responses, and objective biological markers. The studies often include careful monitoring of various parameters to build a comprehensive profile of PT-141’s actions in human research subjects, without implying any therapeutic application. For a deeper understanding of its foundational actions, refer to our page on PT-141’s Mechanism of Action.

Research Focus and Design Characteristics

The nature of the studies registered on ClinicalTrials.gov for PT-141 typically aligns with its established mechanism as a melanocortin receptor agonist. Research has focused on its potential influence on central pathways associated with sexual function, as well as broader neuroendocrine regulation. The study designs often vary in scope, ranging from early-phase investigations primarily assessing tolerability and basic physiological responses in a research context, to later-phase studies designed to gather more extensive data on specific endpoints relevant to neuroendocrine modulation.

Common research endpoints in these registered studies often include a combination of objective and subjective measures. Objective endpoints might involve hormonal assays, neurophysiological assessments, or other quantifiable biological markers. Subjective endpoints typically rely on structured participant-reported outcomes, such as questionnaires or scales designed to capture specific aspects of neuroendocrine or sexual response under controlled research conditions. These data contribute to a broader scientific understanding of PT-141’s profile as a research compound.

Overview of Registered Studies for PT-141

While specific details of each study are proprietary to their respective research teams and publicly accessible on ClinicalTrials.gov, a general overview of the types of research they represent can be informative for other investigators. These studies contribute to a broader understanding of PT-141 within the scientific community, emphasizing its role purely as a research compound. The table below illustrates the generalized characteristics often associated with such registrations:

Study Characteristic	General Description for PT-141 Research
Number of Studies Registered	4
Typical Research Phases Observed	Early-phase (e.g., Phase 1, Phase 2a) focused on tolerability and preliminary physiological data collection in a research setting.
Primary Research Focus Areas	Neuroendocrine regulation, central pathways related to sexual function.
Common Research Participants	Adult subjects, typically healthy volunteers or those with specific research-relevant profiles (e.g., specific neuroendocrine or sexual health research criteria).
General Research Endpoints	Pharmacokinetic profiles, physiological responses (e.g., hormonal changes, cardiovascular parameters), participant-reported outcomes (e.g., specific scales for neuroendocrine or sexual responses).

Methodological Challenges and Future Research Directions for PT-141

Research into PT-141, a melanocortin agonist acting centrally, presents a unique set of methodological challenges. One primary hurdle lies in accurately modeling its complex central nervous system (CNS) effects. Preclinical in vitro models, while valuable for initial receptor binding and signaling pathway analysis, often struggle to fully replicate the intricate neurocircuitry and feedback loops present in vivo. This necessitates careful translation of findings from cellular or tissue culture experiments to animal models, and ultimately, to human research studies, always maintaining a strict research-use-only perspective.

Furthermore, the peptide nature of PT-141 introduces challenges related to stability, delivery, and systemic distribution. Ensuring consistent bioavailability and targeting specific CNS regions effectively within research protocols requires sophisticated administration techniques and robust analytical methods. The potential for off-target effects or interactions with other neuroendocrine systems also complicates data interpretation, requiring meticulous experimental design to isolate PT-141’s specific contributions to observed outcomes. Accurate characterization of the peptide’s purity and identity is paramount for reproducible research outcomes, underscoring the importance of resources like a Certificate of Analysis (CoA) for every research batch.

Challenges in Experimental Design and Execution

Designing research studies with PT-141 demands rigorous consideration of several factors. Selecting appropriate animal models is critical, as species-specific differences in melanocortin receptor distribution and signaling can impact the translatability of preclinical findings. Establishing suitable dosage ranges that evoke measurable physiological responses without introducing confounding systemic effects is another common challenge. In studies involving human research subjects, participant heterogeneity in neuroendocrine profiles or baseline responses requires careful stratification and statistical analysis to ensure robust and reliable data.

Moreover, the subjective nature of some research endpoints, particularly those related to sexual function or mood, requires the use of validated and standardized assessment tools. Bias in participant reporting or researcher interpretation must be minimized through double-blinded protocols and objective physiological measurements whenever possible. The long-term stability of PT-141 under various storage conditions and during experimental preparation is also a practical concern, impacting the consistency and reliability of results across different research batches and over time.

Promising Avenues for Future PT-141 Research

Building upon the existing body of 108 PubMed publications and the ongoing registered studies, future research directions for PT-141 are diverse and promising. A key area involves a deeper elucidation of its specific binding profile across different melanocortin receptor subtypes (MC1R-MC5R) and how this differential activation translates into distinct physiological outcomes. Advanced imaging techniques could offer insights into PT-141’s distribution within the CNS and its precise neuroanatomical targets, expanding our understanding beyond generalized receptor agonism.

Further investigation into potential novel research applications beyond its current focus on neuroendocrine and sexual health research is also warranted. Given the broad roles of the melanocortin system, researchers might explore PT-141’s influence on other CNS-mediated responses, such as appetite regulation, inflammation, or pain perception, strictly within a research context. Development of novel peptide delivery systems that enhance CNS bioavailability or enable more localized administration could also significantly advance the field, offering researchers more precise tools for investigation. Finally, comparative studies with other melanocortin system modulators could help delineate PT-141’s unique pharmacological profile.

Specificity of Receptor Subtype Activation: Further research into the precise MCR subtypes involved in PT-141’s observed effects and the functional consequences of differential activation.
Advanced CNS Distribution Studies: Utilizing techniques like PET imaging to map PT-141’s brain distribution and target engagement in research models.
Novel Research Applications: Exploring PT-141’s potential influence on other CNS-mediated functions such as nociception, inflammation, or cognitive processes in preclinical models.
Optimized Delivery Systems: Investigating innovative methods for peptide administration to improve CNS penetration and targeted delivery in research settings.
Comparative Pharmacology: Head-to-head studies with other melanocortin agonists or antagonists to better characterize PT-141’s unique mechanistic profile.

Ethical and Regulatory Frameworks Governing PT-141 Research Compound Use

PT-141, as a research compound, is strictly intended for laboratory investigations, in vitro studies, and animal research. It is imperative for all researchers to understand and adhere to the fundamental principle that PT-141 is not approved for human consumption, therapeutic use, or any form of medical treatment. Its classification as a “research-use-only” chemical dictates a stringent ethical and regulatory framework that governs its procurement, handling, experimentation, and disposal. Failure to comply with these guidelines can have significant legal and ethical repercussions for individuals and institutions.

For any research involving living subjects, whether animal models or, in the case of registered studies, human research participants, strict ethical oversight is mandatory. Institutional Animal Care and Use Committees (IACUCs) for animal studies and Institutional Review Boards (IRBs) for human research protocols are critical bodies that review and approve all experimental designs. These committees ensure that research is conducted in accordance with established ethical principles, prioritizing the welfare of subjects, minimizing potential harm, and ensuring informed consent (where applicable for human research) within the research-only context.

Distinction Between Research Compounds and Approved Therapeutics

It is crucial to emphasize the clear distinction between research compounds like PT-141 and pharmaceutical products approved for clinical use. PT-141 has not undergone the rigorous evaluation processes required for regulatory approval as a therapeutic agent for any human condition. Therefore, any discussion or application of PT-141 outside of controlled laboratory or preclinical research settings, strictly for investigational purposes, is inappropriate and non-compliant with its “research-use-only” designation. This distinction must always guide researcher communication, experimental design, and public representation of the compound’s status.

Researchers must also be cognizant of regulatory requirements concerning the sourcing and handling of research peptides. Suppliers of PT-141, such as Royal Peptide Labs, are committed to providing high-purity research compounds for scientific investigation. However, the ultimate responsibility for compliance with all local, national, and international regulations pertaining to the purchase, possession, storage, and experimental use of PT-141 rests squarely with the researcher and their institution. This includes understanding import/export laws, material safety data sheet (MSDS) guidelines, and institutional biosafety protocols.

Navigating Regulatory Compliance for Research Peptides

Maintaining meticulous records is an integral part of ethical and regulatory compliance. Researchers should document all aspects of PT-141’s lifecycle within their laboratory, from purchase and receipt to experimental use and final disposal. This includes maintaining detailed logs of batch numbers, storage conditions, and quantities used. Proper storage and handling are paramount to maintaining the integrity and stability of the research compound, ensuring the reliability of experimental results. Researchers are encouraged to consult resources such as our guide on PT-141 Storage and Handling to ensure optimal conditions.

Finally, responsible disposal of PT-141 and any contaminated materials is a critical component of regulatory compliance and environmental stewardship. Researchers must follow institutional guidelines for chemical waste disposal, which are typically designed to prevent environmental contamination and protect personnel. Adherence to these comprehensive ethical and regulatory frameworks ensures the scientific integrity of PT-141 research and upholds the highest standards of responsible scientific inquiry.

Frequently Asked Questions

What is PT-141?

PT-141, also known by its investigational alias Bremelanotide, is a synthetic peptide classified as a melanocortin receptor agonist. It is a compound of significant interest in neuroendocrine and sexual-health research, primarily due to its distinct mechanism of action.

Q: What is the mechanism of action of PT-141?

A: PT-141 functions as an agonist primarily at melanocortin receptors, specifically MC3R and MC4R within the central nervous system. Through this agonistic activity, PT-141 is hypothesized to activate intracellular signaling cascades, which are currently under investigation for their potential influence on various physiological pathways, particularly those related to neuroendocrine regulation and sexual responses in diverse research models.

Q: In what research areas has PT-141 been investigated?

A: Research into PT-141 largely centers on its potential applications in neuroendocrine and sexual-health models. Studies explore its effects on pathways involved in motivation, arousal, and other central nervous system-mediated responses. Its activity at melanocortin receptors positions it as a valuable tool for understanding complex neurobiological processes.

Q: Are there any aliases for PT-141 in research literature?

A: Yes, PT-141 is widely recognized by its investigational designation, Bremelanotide. Researchers will frequently encounter both names used interchangeably in scientific publications, research databases, and discussions surrounding this compound.

Q: How many research publications discuss PT-141?

A: As of the latest review, PT-141 (Bremelanotide) has been the subject of substantial scientific inquiry. There are 108 PubMed-indexed publications that have explored various aspects of PT-141’s activity, mechanisms, and potential research applications across a range of studies.

Q: Has PT-141 been evaluated in human research studies registered on ClinicalTrials.gov?

A: Yes, PT-141 (Bremelanotide) has been the focus of registered research studies on ClinicalTrials.gov. Currently, there are 4 registered studies listed, indicating ongoing or completed investigations into its effects within controlled research environments, contributing to the broader understanding of its biological properties.

Q: What is the significance of PT-141’s classification as a melanocortin agonist for research purposes?

A: Its classification as a melanocortin agonist means PT-141 interacts with the melanocortin system, a complex network of receptors and ligands involved in numerous physiological processes, including energy homeostasis, inflammation, and sexual function. Studying PT-141 provides a precise pharmacological tool for researchers to selectively probe these specific pathways, particularly those related to the central nervous system’s role in sexual responses and neuroendocrine regulation.

Q: What are appropriate storage conditions for PT-141 as a research peptide?

A: For optimal stability and to maintain the integrity of research-grade PT-141, it is generally recommended to store the lyophilized powder at -20°C or colder, protected from light and moisture. Once reconstituted, solutions should be used promptly or stored refrigerated at 2-8°C for short durations, or preferably frozen at -20°C or colder in single-use aliquots to prevent degradation from repeated freeze-thaw cycles, ensuring reliable results for future research use.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.